CD274 and breast neoplasm: Even though there was no significant difference in PD-L1 + and PD-L2 + breast tumor cells between vehicle and adriamycin groups, combination therapy with adriamycin and eFT-508 showed a synergistic effect compared to both adriamycin and eFT-508 monotherapy groups (Fig. 6C–E).